At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 50 enrolled
Drug / intervention
PF-05231023 +4 moredrug
Likely dose
PF-05231023 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Placebo-Controlled Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating PF-05231023 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 50 participants across 5 sites.
Detailed Summary
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple ascending doses of PF-05231023.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedJul 2011
Primary CompletionMay 2012
TodayJul 2026
First PostedJul 18, 2011
Enrollment StartJul 1, 2011
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.0 years ago
Interventions
PF-05231023drug
5 mg IV twice a week for 4 weeks
PF-05231023drug
25 mg IV twice a week for 4 weeks
PF-05231023drug
100 mg IV twice a week for 4 weeks
PF-05231023drug
200 mg IV twice a week for 4 weeks
Placeboother
0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks